Future Fertility, a Toronto, Canada-based fertility technology company developing AI-enabled and non-invasive fertility solutions to optimize clinical decision making in fertility care and in vitro fertilization (IVF), raised a Series A financing round of undisclosed amount.
The round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany, a global fertility leader), with participation from Whitecap Venture Partners.
Led by Diana Olusanmi, Chief Executive Officer, and Dr Dan Nayot, Future Fertility aims to harness the power of AI to improve fertility care and IVF outcomes, lower its costs, and alleviate emotional stress of the patient journey. The targeted application of AI in the IVF process also has the potential to deliver new insights contributing to better understanding of mechanisms that underlie fertility pathologies.
Future Fertility’s first non-invasive AI solution can detect features of a human egg that are invisible to the eye and can predict the likelihood of fertilization and embryo (blastocyst) development. The product is already used in a number of innovative clinics around the world. Beyond its flagship egg prediction software product “Violet” developed for patients underdoing oocyte cryopreservation, Future Fertility has additional AI solutions in its pipeline, with the potential to improve key decisions in the 2.5 million IVF cycles each year, for which no non-invasive tools existed to date.